Nova Publishers
My Account Nova Publishers Shopping Cart
HomeBooksSeriesJournalsReference CollectionseBooksInformationSalesImprintsFor Authors
            
  Top » Catalog » Books » Biology » Biology - General » Advances in Medicine and Biology. Volume 50 Chapters » My Account  |  Cart Contents  |  Checkout   
Quick Find
  
Use keywords to find the product you are looking for.
Advanced Search
What's New? more
Fetal Alcohol Syndrome: Recognition, Differential Diagnosis and Long-Term Effects
$82.00
Shopping Cart more
0 items
Information
Shipping & Returns
Privacy Notice
Conditions of Use
Contact Us
Notifications more
NotificationsNotify me of updates to Mesenchymal Stem Cells versus other Marrow-Derived Progenitor Cells in Angiogenesis and Vasculogenesis (pp. 89-106)
Tell A Friend
 
Tell someone you know about this product.
Mesenchymal Stem Cells versus other Marrow-Derived Progenitor Cells in Angiogenesis and Vasculogenesis (pp. 89-106) $100.00
Authors:  (Joanne McBane, Marc Ruel, Erik J. Suuronen, Division of Cardiac Surgery, Department of Cellular and Molecular Medicine, University of Ottawa Heart Institute, Canada)
Abstract:
Ischemia resulting from decreased blood flow is a central problem in cardiovascular disease and in most end-organ complications associated with diabetes. The lack of proper blood supply may also contribute to the failure of organ and tissue transplantations (e.g. pancreatic islet cell transplantation).
Cell-based therapies to induce blood vessel regeneration through angiogenesis or vasculogenesis in vivo are a major area of research in the field of regenerative medicine. Recruitment of new endothelial cells or differentiation of mesenchymal stem cells (MSCs) or endothelial progenitor cells (EPCs) to endothelial cells may be a key to stimulating angiogenesis or vasculogenesis in vivo. Evaluation of early and late outgrowth peripheral blood-derived EPCs suggest that both have potential to stimulate angiogenesis.
Cell therapy trials using bone marrow stem cells and progenitor cells applied to ischemic disease states have yielded promising but modest results, with a definite opportunity for improvement. Tissue engineering constitutes one strategy to enhance the therapeutic effect of stem/progenitor cells. Matrix scaffolds with or without the use of growth factors have been developed and are under investigation for improving delivery and/or recruitment of MSCs and EPCs. This chapter discusses the current and potential uses of MSCs and EPCs in therapeutic angiogenesis and vasculogenesis in vitro and in vivo. 


Available Options:
Version:
Special Focus Titles
01.Violent Communication and Bullying in Early Childhood Education
02.Cultural Considerations in Intervention with Women and Children Exposed to Intimate Partner Violence
03.Chronic Disease and Disability: The Pediatric Lung
04.Fruit and Vegetable Consumption and Health: New Research
05.Fire and the Sword: Understanding the Impact and Challenge of Organized Islamism. Volume 2

Nova Science Publishers
© Copyright 2004 - 2020

Mesenchymal Stem Cells versus other Marrow-Derived Progenitor Cells in Angiogenesis and Vasculogenesis (pp. 89-106)